BMY’s HCV approach in all markets except Japan is to focus on GT3 and niche market segments. (Source: today’s DB webcast.) This confirms that (contrary to what was written in BioCentury), BMY does not intend to submit an NDA or MAA for its 3-DAA regimen for GT1 patients.